Switching to Tildrakizumab for Moderate to Severe Plaque Psoriasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effects of transitioning patients with moderate to severe plaque psoriasis from their current biologic treatment to tildrakizumab. It focuses on patient-reported outcomes, assessing changes in psoriasis intensity and quality of life before and after the switch. The study also explores the reasons behind patients' decisions to switch biologics, whether due to treatment failure, adverse events, or personal preferences.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Written informed consent.
2. \>=18 years of age.
3. Moderate-to-severe plaque psoriasis currently treated with a biologic therapy (TNFα antagonist, IL12/23 antagonist, IL17 antagonist).
4. Switch to tildrakizumab due to:

   1. primary or secondary treatment failure (PASI \>= 3 or ΔPASI \< 75 and/or DLQI \> 5)
   2. adverse events, contraindication, intolerance
   3. patient wish (dosing regimen), lack of adherence, or other, including nonmedical reason
5. Treatment with tildrakizumab planned in the frame of clinical practice.

Exclusion Criteria:

1. Patient appears to be unwilling or unable to comply with the requirements of the study or who, in the opinion of the Investigator, should not participate in the study.
2. \>=3 previous biologic treatments in the last 3 years.
3. Participation in a clinical trial simultaneous to participation in SW-ATCH.
4. Any condition preventing prescription of Tildrakizumab according to the SmPC, including but not restricted to any contraindication or history of hypersensitivity or intolerance.
5. Patient dependent on the Investigator.
6. Previous treatment with Tildrakizumab.

Where it's running

• Gesundheitszentrum Citypark Graz
  Graz, Styria, Austria Recruiting

Study contacts

• Study coordinator: Senior Director Regional Medical Affairs
• Email: medicalat@almirall.com
• Phone: +43 0 15953960

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How safe and well ZP9830 works in people with plaque psoriasis over 8 weeks

  This study tests whether ZP9830 is safe and tolerable in adults with plaque psoriasis for 8 weeks, with a comparison to placebo.

  Recruiting Phase 1 Zealand Pharma · Leiden, South Holland · NCT07733089

• Secukinumab retention in adults with plaque psoriasis and MASLD in Spain

  This study tests how long people with plaque psoriasis and MASLD stay on secukinumab in real-world Spain, using EMR data from several hospitals.

  Recruiting at 9 sites Novartis · Badalona, Barcelona and 8 other locations · NCT07683065

• Long-term ORKA-001 treatment for adults with plaque psoriasis

  This open-label extension will try ORKA-001 long-term in adults with moderate-to-severe plaque psoriasis who completed a previous ORKA-001 study.

  Recruiting at 39 sites Phase 2 Oruka Therapeutics, Inc. · Phoenix, Arizona and 38 other locations · NCT07449702

• Tildrakizumab for symptoms and quality of life in Canadians with moderate-to-severe plaque psoriasis (Fitzpatrick III+)

  This study will test how tildrakizumab affects symptoms, safety, and quality of life in adults in Canada with moderate-to-severe plaque psoriasis who are starting treatment through the ILUMYA SUPPORT® Program and have Fitzpatrick skin types III or higher.

  Recruiting at 7 sites Chronicle Academy · Burlington, Ontario and 6 other locations · NCT07370766

• D-2570 oral treatment for adults with moderate to severe plaque psoriasis

  This trial tests whether the oral medicine D-2570 helps adults with moderate to severe plaque psoriasis compared with placebo and an approved oral drug.

  Recruiting Phase 3 InventisBio Co., Ltd · Shanghai, Shanghai Municipality · NCT07326813

• ICP-332 versus placebo for moderate-to-severe plaque psoriasis

  This will test whether ICP-332 helps adults with moderate-to-severe plaque psoriasis compared with a placebo.

  Recruiting Phase 2 Beijing InnoCare Pharma Tech Co., Ltd. · Shanghai, Shanghai Municipality · NCT07251998

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.